Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
Eli Lilly and Company has announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.
(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Data suggests that dramatic weight loss, including via GLP-1 drugs, could save Americans big bucks in healthcare spending.
Airlines don't always honor requests to protect the health of people with food allergies during flights, a new study found.
Lilly’s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world.
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
In a study trial, Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in weight loss efficacy. The study was conducted by ...
Eli Lilly is one of the two current leaders in the weight loss space, along with Novo Nordisk. And while Viking and others are working on intriguing alternatives to Mounjaro, Zepbound, Ozempic ...